ExTRACT-TIMI 25 in perspective: Key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy

Journal of Thrombosis and Thrombolysis

Volumn 27, Issue 1, 2009, Pages 1-10

  Thomas, Deepak ^a   Giugliano, Robert P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticoagulants; Enoxaparin; ExTRACT TIMI25; Myocardial infarction; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; RETEPLASE; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; AGE; ARTICLE; BLEEDING; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZATION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; SEX DIFFERENCE; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; COMBINED MODALITY THERAPY; COMORBIDITY; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; STROKE; THROMBOLYTIC THERAPY; TICLOPIDINE;

EID: 60749135287     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0284-0     Document Type: Article

References (36)

1. Rosamond W, Flegal K, Friday G et al (2007) Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115:e69-e171. doi: 10.1161/CIRCULATIONAHA.106.179918
2. Antman EM, Hand M, Armstrong PW et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210-247. doi: 10.1016/j.jacc.2007.10.001
3. Jollis JG, Mehta RH, Roettig ML et al (2006) Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design. Am Heart J 152:851.e1-11
4. Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477-1488. doi: 10.1056/NEJMoa060898
5. Eagle KA, Goodman SG, Avezum A et al (2002) Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: Findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359:373-377. doi: 10.1016/S0140-6736(02)07595-5
6. Armstrong PW (2002) Coronary reperfusion: Numerators searching for denominators. Lancet 359:371-372. doi: 10.1016/S0140-6736(02)07588-8
7. Weaver WD (2003) All hospitals are not equal for treatment of patients with acute myocardial infarction. Circulation 108:1768-1771. doi: 10.1161/01.CIR.0000097559.09335.4A
8. Antman EM (2001) The search for replacements for unfractionated heparin. Circulation 103:2310-2314
9. Antman EM, Morrow DA, McCabe CH et al (2005) Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 149:217-226. doi: 10.1016/ j.ahj.2004.08.038
10. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. doi: 10.1159/000130554
11. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 130:461-470
12. Scirica BM, Morrow DA, Sadowski Z et al (2007) A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: The ExTRACT-TIMI 25 ECG study. Eur Heart J 28:2070-2076. doi: 10.1093/eurheartj/ehm210
13. Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation. Circulation 102:2031-2037
14. Ruff CT, Wiviott SD, Morrow DA et al (2007) TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction. Am J Med 120:993-998. doi: 10.1016/j.amjmed.2007.08.020
15. Wiviott SD, Morrow DA, Frederick PD et al (2004) Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: A simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 44:783-789
16. Goodman SG, Fitchett D, Armstrong PW et al (2003) Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 107:238-244. doi: 10.1161/01.CIR.0000050144.67910.13
17. Gibson CM, Murphy SA, Montalescot G et al (2007) Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49:2238-2246. doi: 10.1016/j.jacc.2007.01.093
18. Sabatine MS, Morrow DA, Montalescot G et al (2005) Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial. Circulation 112:3846-3854. doi: 10.1161/CIRCULATIONAHA.105.595397
19. Sabatine MS, Morrow DA, Dalby A et al (2007) Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J Am Coll Cardiol 49:2256-2263. doi: 10.1016/j.jacc.2007.01.092
20. Giraldez RR, Nicolau JC, Corbalan R et al (2007) Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: An ExTRACT-TIMI 25 analysis. Eur Heart J 28:1566-1573. doi: 10.1093/ eurheartj/ehm179
21. Mega JL, Morrow DA, Ostör E et al (2007) Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation 115:2822-2828. doi: 10.1161/ CIRCULATIONAHA.106.679548
22. White HD, Braunwald E, Murphy SA et al (2007) Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: Results from ExTRACT-TIMI 25. Eur Heart J 28:1066-1071. doi: 10.1093/eurheartj/ehm081
23. Alexander KP, Newby LK, Armstrong PW et al (2007) Acute coronary care in the elderly, part II: ST-segment-elevaAion myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. Circulation 115:2570-2589. doi: 10.1161/CIRCULATIONAHA.107.182616
24. White HD, Aylward PE, Huang Z et al (2005) Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: Results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 112:3391-3399. doi: 10.1161/CIRCULATIONAHA.105.551143
25. Fried LF, Shlipak MG, Crump C et al (2003) Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41:1364-1372. doi: 10.1016/ S0735-1097(03)00163-3
26. Fox KA, Antman EM, Montalescot G et al (2007) The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49:2249-2255. doi: 10.1016/j.jacc.2006.12.049
27. Grundy SM, Benjamin IJ, Burke GL et al (1999) Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 100:1134-1146
28. Aguilar D, Solomon SD, Køber L et al (2004) Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110:1572-1578. doi: 10.1161/ 01.CIR.0000142047.28024.F2
29. Morrow DA, Antman EM, Murphy SA et al (2007) Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J 154:1078-1084. doi: 10.1016/ j.ahj.2007.07.027
30. Murphy SA, Gibson CM, Morrow DA et al (2007) Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: A meta-analysis. Eur Heart J 28:2077-2086. doi: 10.1093/eurheartj/ehm224
31. Assessment of the Safety, Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators (2001) Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358:605-613
32. Ross AM, Molhoek P, Lundergan C et al (2001) Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104:648-652. doi: 10.1161/hc3101.093866
33. Baird SH, Menown IB, McBride SJ et al (2002) Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 23:627-632. doi: 10.1053/ euhj.2001.2940
34. Antman EM, Louwerenburg HW, Baars HF et al (2002) Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 105:1642-1649. doi: 10.1161/01.CIR.0000013402.34759.46
35. Wallentin L, Goldstein P, Armstrong PW et al (2003) Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 108:135-142. doi: 10.1161/01.CIR.0000081659.72985.A8
36. Kindermann M, Adam O, Werner N et al (2007) Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol 96:767-786. doi: 10.1007/s00392-0591-z